More Publications by © Chronicle Companies

n+p.PNG
Advertise with Derm.city
Chronicle Companies
Terms of Use Policy
Order "To Heal the Skin"

© Chronicle Companies 2018

Powered by Skin Chronicle International

  • Twitter - Black Circle
  • Facebook - Black Circle
  • YouTube - Black Circle
  • Home

  • Skin Chronicle

  • Primers for your Patient

  • Skin Spectrum Summit

  • Chronicle

  • Contact

  • More...

    General
    News
    Skin Cancer

    Pembrolizumab reduced recurrence risk of stage 3 melanoma

    April 16, 2018

    |

    by Bianca Quijano

    Patients with stage 3 melanoma were 43% less likely to have a recurrence after a one-year course of the humanized antibody, pembrolizumab. Specifically, the 12-month recurrence-free survival rate for patients randomized to pembrolizumab was 75.4%, in contrast to the 61% for those randomized to placebo, according to a study presented at the American Association for Cancer Research Annual Meeting 2018 in Chicago and published online in The New England Journal of Medicine (Apr. 15, 2018).

     

    “We were pleased to see that adjuvant pembrolizumab, given as a flat dose of 200 milligrams every three weeks after surgery for up to a year, which is 18 doses, significantly reduced the risk of recurrence for patients with high-risk stage 3 melanoma that has been completely resected,” said Dr. Alexander M. M. Eggermont, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France in a press release. “We hope that these data will lead to regulators in the United States and Europe approving pembrolizumab as a new treatment option for these patients.”

     

    A total of 1,019 patients with stage 3 melanoma, who were at high risk of recurrence after surgery were randomized 1:1 to a flat dose of 200 milligrams of pembrolizumab or placebo. Participants were required to have either stage 3A melanoma (patients with stage N1a melanoma had to have at least one micro-metastasis measuring >1 mm in greatest diameter) or stage 3B or 3C disease, with no in-transit metastases as defined by the American Joint Committee on Cancer 2009 classification, 7th edition. As Dr. Eggermont explained, they received treatment every three weeks for a total of 18 doses, or until disease recurrence or unacceptable toxicity transpired.

     

    After a median follow-up of 15 months, 135 of the 514 patients treated with pembrolizumab and 216 of the 505 patients treated with placebo had been diagnosed with recurrent disease or had died. Additionally, 14.7% of participants in the pembrolizumab group experienced adverse events related to the trial regimen, compared to 3.4% of patients in the placebo group. One treatment-related death due to myositis was also reported in the pembrolizumab group.

     

    The study conducted by Dr. Alexander M.M. Eggermont (pictured above) and his colleagues received support from the European Organisation for Research and Treatment of Cancer (EORTC) and the pharmaceutical company, Merck. Photo courtesy of the American Association for Cancer Research. 

     

    The positive effects of the humanized antibody were similar when patients with PD-L1-positive and PD-L1-negative tumours were examined separately. Among the 852 patients with PD-L1-positive tumours, those on pembrolizumab were 46% less likely to have a recurrence or death event compared with those who were given placebo. Among the 116 patients with PD-L1-negative tumours, those randomized to pembrolizumab were 53% less likely to have a recurrence or death event.

     

    “An important aspect of this trial is that patients randomized to placebo who have recurrence are offered access to pembrolizumab,” said Dr. Eggermont. “This cross-over design is unique in the world of adjuvant trials in melanoma and will permit us to analyze if adjuvant therapy with pembrolizumab right after surgery is better or not than treating only those who relapse and start treatment at relapse.”

     

    Tags:

    melanoma

    pembrolizumab

    Dr. Alexander M. M. Eggermont

    American Association for Cancer Research

    Please reload

    Featured Posts

    High-dose brachytherapy for BCC, SCC in older patients

    December 6, 2019

    Study: Makeup Products May Harbor Dangerous Bacteria

    December 4, 2019

    Newborn's immune system detects harmful skin bacteria

    December 2, 2019

    Topical rapamycin may slow skin aging

    November 29, 2019

    Statin medications may leave patients vulnerable to skin infections

    November 27, 2019

    Genes show how much sun exposure could lead to melanoma

    November 25, 2019

    Atopic eczema increases fracture risk

    November 22, 2019

    Identifying hyperhotspots in genome could be key in preventative skin cancer treatment

    November 20, 2019

    New guidelines for opioid prescribing practices for dermatologists

    November 18, 2019

    More effective rituximab dosing for pemphigus identified

    November 15, 2019

    Please reload

    Archive

    December 2019 (3)

    November 2019 (11)

    October 2019 (11)

    September 2019 (13)

    August 2019 (13)

    July 2019 (12)

    June 2019 (11)

    May 2019 (17)

    April 2019 (15)

    March 2019 (13)

    February 2019 (11)

    January 2019 (13)

    December 2018 (12)

    November 2018 (13)

    October 2018 (14)

    September 2018 (9)

    August 2018 (9)

    July 2018 (9)

    June 2018 (13)

    May 2018 (11)

    April 2018 (13)

    March 2018 (13)

    February 2018 (14)

    January 2018 (12)

    December 2017 (6)

    November 2017 (11)

    October 2017 (5)

    September 2017 (4)

    August 2017 (6)

    July 2017 (10)

    June 2017 (12)

    May 2017 (17)

    April 2017 (12)

    March 2017 (19)

    February 2017 (11)

    January 2017 (13)

    December 2016 (11)

    November 2016 (13)

    October 2016 (16)

    September 2016 (16)

    August 2016 (14)

    July 2016 (16)

    June 2016 (16)

    May 2016 (22)

    April 2016 (17)

    March 2016 (15)

    February 2016 (12)

    January 2016 (11)

    December 2015 (13)

    November 2015 (19)

    October 2015 (13)

    September 2015 (15)

    July 2015 (3)

    June 2015 (22)

    March 2015 (3)

    Please reload

    Follow Us
    • Grey Facebook Icon
    • Grey YouTube Icon
    • Grey Instagram Icon
    • Grey Twitter Icon